The present disclosure pertains to a new synthetic method for the preparation of 2-methyl-2-hydroxyheptane and 2-methyl-2-alkoxyheptanes, which are valuable commodities for use in flavors, fragrances and various personal care products, such as cosmetics.

The present disclosure pertains to a new synthetic method for the preparation of 2-methyl-2-hydroxyheptane and 2-methyl-2-alkoxyheptanes, which are valuable commodities for use in flavors, fragrances and various personal care products, such as cosmetics.

The present invention provides a novel intermediate as well as novel polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide compound represented by the following structural formula-1 and processes for their preparation.

The present invention provides a novel intermediate as well as novel polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide compound represented by the following structural formula-1 and processes for their preparation.

A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

A process for the production of concentrated aqueous solutions of hydrazine hydrate includes preparation of hydrazine hydrate by a ketazine method using 50-70% hydrogen peroxide, recyclable solid acetamide and ammonium acetate activator for ketazine formation, and catalyst-free hydrolysis of ketazine to provide aqueous solutions of hydrazine hydrate in an energy efficient manner.

A process for the production of concentrated aqueous solutions of hydrazine hydrate includes preparation of hydrazine hydrate by a ketazine method using 50-70% hydrogen peroxide, recyclable solid acetamide and ammonium acetate activator for ketazine formation, and catalyst-free hydrolysis of ketazine to provide aqueous solutions of hydrazine hydrate in an energy efficient manner.

A process for the production of concentrated aqueous solutions of hydrazine hydrate includes preparation of hydrazine hydrate by a ketazine method using 50-70% hydrogen peroxide, recyclable solid acetamide and ammonium acetate activator for ketazine formation, and catalyst-free hydrolysis of ketazine to provide aqueous solutions of hydrazine hydrate in an energy efficient manner.

Processes for preparing (((3aR,6aS)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone

##STR00001##

are described, which are useful for commercial manufacturing. Said compound is an orexin receptor modulator and may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia and depression.